Back to Journals » OncoTargets and Therapy » Volume 9

Clinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-oesophageal junction adenocarcinoma

Authors Davidson M, Smyth E, Cunningham D

Received 1 December 2015

Accepted for publication 1 July 2016

Published 25 July 2016 Volume 2016:9 Pages 4539—4548


Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 2

Editor who approved publication: Dr Faris Farassati

Michael Davidson, Elizabeth C Smyth, David Cunningham

Department of Gastrointestinal Cancer Research, The Royal Marsden Hospital NHS Foundation Trust, London, UK

Cancers of the stomach and gastro-esophageal junction represent a significant challenge in oncology. Despite some recent advances in genetic categorization and the development of novel agents, outcomes remain poor. The vascular endothelial growth factor receptor 2 monoclonal antibody ramucirumab is the first targeted therapy to improve survival in a molecularly unselected population, and represents a valuable new treatment option. This review describes the current treatment landscape for advanced disease, evaluates existing and ongoing research into ramucirumab, and discusses its current and potential future therapeutic role.

Keywords: advanced gastric cancer, ramucirumab, paclitaxel, angiogenesis inhibitors

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]